Veterans Integrated Service Network 19 established a Blanket Purchase Agreement with Exosome Diagnostics Inc. on September 15, 2026, with a ceiling of $1,124,125 and an ultimate completion date of September 14, 2027, against the GSA Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II).
The BPA procures non-invasive prostate cancer testing services using urine-based molecular liquid biopsy test kits that generate risk scores to differentiate high-risk from low-risk aggressive prostate cancer. The test algorithm is based on RNA marker analysis and does not require digital rectal examination prior to specimen collection. The contractor must be CLIA-certified and Medicare/Medicaid-approved, maintain HIPAA compliance, and meet Clinical Laboratory Improvement Act and Clinical and Laboratory Standards Institute standards for accuracy and precision. Test kits are shipped directly to patients' homes with prepaid return labels or to specified VISN 19 laboratory locations, with results reported within five business days of laboratory receipt. All services—requisition forms, collection supplies, shipping, testing, result reporting, and consultative services—are provided at no additional charge on a firm-fixed-price basis.
Place of performance includes nine VISN 19 laboratory facilities across Colorado, Montana, Oklahoma, and Utah, with primary administrative site at 1700 N Wheeling Street, Aurora, Colorado. NAICS code 621511 applies; PSC code is Q301.